C5 and neuromyelitis optica: Eculizumab (anti-C5 antibody) is an example of an FDA- and EMA-approved complement-inhibitory drug to treat patients suffering from paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder (28).